Santa Fe Community College District 5.00% General Obligation Bonds, Series A, due August 1, 2025

Company Overview

Business Model: Movano Inc., dba Movano Health, is developing a platform to deliver purpose-driven healthcare solutions by integrating medical-grade, high-quality data into consumer health devices. The Company's initial commercial product, the Evie Ring, launched in November 2023 as a general wellness device. In November 2024, Movano Health received FDA 510(k) clearance for the pulse oximetry feature in its EvieMED Ring, positioning it as a medical device to be sold via prescription. The Company is also developing a patented and proprietary System-on-a-Chip ("SoC") for non-invasive continuous glucose monitoring ("CGM") and cuffless blood pressure monitoring, with the long-term goal of bringing a Class II FDA-cleared device to market. Revenue is generated from the sale of Evie Rings, portable chargers, charging cables, ring sizers, and mobile applications, which include customer support and future software updates.

Market Position: Movano Health aims to sit at the intersection of the medical and consumer device markets. The Evie Ring is a wearable designed specifically for women, offering a combination of health and wellness metrics. The EvieMED Ring holds a unique competitive advantage as one of the first patient wearables with FDA clearance on the entire system (hardware and software) for pulse oximetry (pulse rate and SpO2). The Company's proprietary SoC is highlighted as the smallest ever patented and proprietary integrated circuit designed specifically for blood pressure or CGM systems, leveraging multiple antennas and frequencies for precision. Movano Health believes its future non-invasive, cuffless, wearable, and affordably priced CGM and blood pressure solutions will provide a competitive edge in the substantial diabetes and hypertension markets, which saw estimated industry sales of over $6.3 billion in 2023 for CGMs and approximately $5.0 billion in 2024 for blood pressure monitoring devices, respectively.

Recent Strategic Developments:

• Product Launches & Clearances:
  • November 2023: Launched the Evie Ring as a general wellness device.
  • November 2024: Received FDA 510(k) clearance for the pulse oximetry feature in the EvieMED Ring.
• Clinical Studies & Technology Advancement:
  • 2024 and early-2025: Conducted three Institutional Review Board ("IRB") approved blood pressure clinical studies incorporating the proprietary SoC.
  • October 2023: Announced results of an IRB-approved blood pressure clinical study with the SoC, demonstrating an overall mean absolute difference (MAD) of 5.9 mmHg, which is below the 7 mmHg MAD standard for wearable, cuffless blood pressure measuring devices (IEEE1708a-2019).
  • January 2024: Completed a second pivotal hypoxia study for heart rate and SpO2 accuracy, following a successful pilot study in July 2022 and a first pivotal study in October 2022, consistently achieving a margin of error well below the FDA’s 3.5% requirement for SpO2.
• Strategic Partnerships: Formed a strategic partnership with a leading specialty foundry for manufacturing and supplying its integrated circuits.

Geographic Footprint: Movano Health's revenue from the sale of the Evie Ring has been generated exclusively in the United States. The Company established Movano Ireland Limited as a wholly owned subsidiary in April 2021, though its operations have not been significant.

Financial Performance

Revenue Analysis

Profitability Metrics:

• Gross Margin: -196.8% (2024)
• Operating Margin: -2391.1% (2024)
• Net Margin: -2342.2% (2024)

Investment in Growth:

• R&D Expenditure: $11.2 million (1120% of revenue)
• Capital Expenditures: $8 thousand
• Strategic Investments: Significant resources are allocated to research and development activities for the Evie Ring, EvieMED Ring, and the proprietary SoC, including ongoing clinical studies for non-invasive glucose and cuffless blood pressure monitoring.

Capital Allocation Strategy

Shareholder Returns:

• Share Repurchases: Not disclosed.
• Dividend Payments: Movano Health has never paid cash dividends and does not anticipate paying any in the foreseeable future, intending to reinvest all earnings into the business.
• Future Capital Return Commitments: No specific commitments for future capital returns to shareholders were disclosed.

Balance Sheet Position:

• Cash and Equivalents: $7.9 million (as of December 31, 2024)
• Total Debt: $0 (excluding lease liabilities)
• Net Cash Position: $3.9 million (Cash and Equivalents less Total Liabilities)
• Debt Maturity Profile:
  • Operating Lease Liabilities (current portion): $169 thousand (2024)
  • Operating Lease Liabilities (long-term portion): $502 thousand (2024)
  • Finance Lease Liabilities (current portion): $17 thousand (2024)
  • Finance Lease Liabilities (long-term portion): $18 thousand (2024)
  • Future minimum lease payments: $284 thousand (2025), $290 thousand (2026), $280 thousand (2027).

Cash Flow Generation:

• Operating Cash Flow: $(22.5) million
• Free Cash Flow: $(22.5) million (Operating Cash Flow less Capital Expenditures)

Operational Excellence

Production & Service Model: Movano Health is developing a platform for medical-grade data in consumer health devices. The Evie Ring, a general wellness device, and the EvieMED Ring, an FDA 510(k) cleared medical device for pulse oximetry, utilize optical sensors, an accelerometer, battery, charging integrated circuit, flash memory, and Bluetooth for data communication. Future products are planned to incorporate patented RF technology, leveraging ultra-wideband multi-antenna RF with advanced signal processing, interference cancellation, machine learning, and cloud connectivity. This technology is designed for miniature, dynamic integrated circuits embeddable in various wearable form factors, aiming to provide real-time data, trending, predictive alerts, and personalized risk profiles.

Supply Chain Architecture: Key Suppliers & Partners:

• Integrated Circuit Manufacturing: Strategic partnership with a leading specialty foundry for manufacturing and supplying integrated circuits.
• Product Manufacturing: Dependence on third-party Original Equipment Manufacturers ("OEMs") to design and manufacture products.
• Research & Development Materials: Dependence on third-party manufacturers to supply products for research and development activities.

Facility Network:

• Principal Office & Laboratory: 6800 Koll Center Parkway, Pleasanton, California. The lease for this office and laboratory space was extended to December 31, 2027.
• Research & Development: Clinical studies are conducted at the Movano Health Clinical Lab.

Market Access & Customer Relationships

Go-to-Market Strategy: Distribution Channels:

• Direct Sales: Initial strategy involves selling directly to consumers and enterprise customers through the Company's website.
• Channel Partners: Plans to expand through retail or other distribution channels, and by partnering with OEMs and value-added resellers ("VARs").
• Strategic Alliances: Partnering with industry partners to integrate Movano Health's technology into new and existing devices.
• EvieMED Ring Distribution: The EvieMED Ring, being a prescription-only medical device, will be distributed through new channels, including durable medical equipment distributors, healthcare institutions, and other healthcare payor and provider channels.

Customer Portfolio:

• Evie Ring: Primarily targets women in the general wellness market.
• EvieMED Ring: Targets clinicians, healthcare providers, payors, and facilities engaged in clinical trials for at-home and/or long-term patient monitoring.
• Future Products: Planned continuous glucose monitoring and cuffless blood pressure devices will target individuals with diabetes, prediabetes, hypertension, and the broader health-conscious population.

Geographic Revenue Distribution:

• United States: 100% of total revenue (from Evie Ring sales in 2024).

Competitive Intelligence

Market Structure & Dynamics

Industry Characteristics: The technology industry, particularly the general wellness, continuous glucose monitoring, and blood pressure monitoring markets, is intensely competitive and characterized by rapid change and frequent new product introductions. The healthcare market is transitioning towards preventative care and longevity, driving increased consumer demand for digital health offerings.

Competitive Positioning Matrix:

Direct Competitors

Primary Competitors:

• General Wellness: Apple, Samsung, Garmin, Fitbit, WHOOP, Oura Health.
• Continuous Glucose Monitoring (CGM): DexCom, Inc., Abbott Laboratories, Medtronic plc, Roche Diagnostics, LifeScan, Inc., Ascensia Diabetes Care Holdings AG, Senseonics Holdings, Inc., Integrity Applications, Inc., Nemaura Medical, Biolinq Inc., Profusa, Inc. (also traditional glucometers).
• Blood Pressure Monitoring: OMRON Corporation, Welch Allyn, A&D Medical, American Diagnostic Corporation, GE Healthcare, Masimo Corporation, Philips, SunTech Medical Inc., Aktiia, Biobeat, Blumio.

Competitive Response Strategy: Movano Health's strategy to maintain competitive advantage centers on developing and deploying its technology on a non-invasive basis, packaged in a wearable device that is painless, cuffless, simple, smart, and competitively priced.

Risk Assessment Framework

Strategic & Market Risks

Market Dynamics: The Company operates in intensely competitive markets subject to rapid change and new product introductions. Estimates of total addressable markets for current and future products may prove incorrect. Macroeconomic conditions, including inflation, interest rates, and overall economic uncertainties, could adversely affect business operations and financial condition. Technology Disruption: Competitors may develop novel technologies that could render Movano Health's technology or products obsolete or uneconomical. The increasing use of artificial intelligence ("AI") presents risks such as flawed algorithms, biased datasets, and potential violations of privacy obligations or intellectual property rights.

Operational & Execution Risks

Supply Chain Vulnerabilities: Movano Health is highly dependent on third-party Original Equipment Manufacturers ("OEMs"), value-added resellers ("VARs"), and other distributors for the design, manufacture, marketing, and distribution of its products. The Company also relies on third-party manufacturers for supplying materials for research and development activities. Failures by these third parties could materially harm the business. Information Technology System Failures: The Company's information technology systems, and those of its contractors, are vulnerable to damage from cyber-attacks, viruses, unauthorized access, and natural disasters, which could disrupt operations, compromise sensitive data, and lead to legal claims or regulatory penalties. Personnel & Growth Management: The Company's success depends on its ability to attract and retain highly qualified managerial and engineering personnel in a competitive talent market. Managing anticipated future growth will place additional demands on financial, technical, operational, and management resources.

Financial & Regulatory Risks

Credit & Liquidity: Movano Health has a limited operating history, a history of operating losses, and has generated negative cash flows from operating activities since inception. There is substantial doubt about the Company's ability to continue as a going concern beyond the second quarter of 2025 without additional capital. The Company's ability to raise additional funds on acceptable terms, or at all, is uncertain. Regulatory & Compliance Risks:

• FDA Clearance/Approval: While the EvieMED Ring has received 510(k) clearance for pulse oximetry, this does not guarantee commercial success. Obtaining additional FDA clearances for other EvieMED Ring monitoring capabilities and for the planned continuous glucose monitoring and cuffless blood pressure solutions is difficult, time-consuming, and may be delayed or unsuccessful. Non-compliance by third-party OEMs with FDA's Quality System Regulations could disrupt manufacturing.
• FCC Regulations: The Company's RF-based technology is subject to Federal Communication Commission ("FCC") regulations, including equipment authorization and human exposure to RF energy. Non-compliance could significantly affect development costs and delay commercialization.
• Healthcare Regulations: Movano Health is subject to federal and state healthcare fraud and abuse laws (e.g., Anti-Kickback Statute, False Claims Act) and patient privacy regulations (e.g., HIPAA, state laws, GDPR). Failure to comply could result in substantial penalties, reputational harm, and adverse effects on business operations.
• Product Recalls: Products may be subject to government-mandated or voluntary recalls due to design or manufacturing defects, which could be expensive, damage reputation, and negatively impact financial performance.
• Healthcare Reform: Legislative and regulatory changes to the healthcare system, aimed at containing or reducing costs, could adversely affect future revenues and profitability.

Geopolitical & External Risks

Geopolitical Exposure: The business is affected by macroeconomic and geopolitical conditions. Climate Change: The effects of global climate change, including natural disasters and extreme weather, could adversely impact the supply chain, raw material availability and cost, energy supply, and transportation, potentially causing physical damage to facilities.

Innovation & Technology Leadership

Research & Development Focus: Core Technology Areas:

• Wearable Health Devices: Development of the Evie Ring and EvieMED Ring, utilizing optical sensors, accelerometers, and Bluetooth for health and wellness metrics (resting heart rate, HRV, SpO2, respiration rate, skin temperature variability, period/ovulation tracking, activity, sleep stages, mood).
• Proprietary System-on-a-Chip (SoC): Development of the smallest patented and proprietary SoC specifically designed for non-invasive blood pressure and continuous glucose monitoring systems, leveraging ultra-wideband multi-antenna RF with advanced signal processing, interference cancellation, and machine learning. Innovation Pipeline: The Company is actively conducting clinical studies with its SoC and developing algorithms to enable non-invasive glucose and cuffless blood pressure monitoring. The end goal is to bring a Class II FDA-cleared device to market with these capabilities, and potentially other health data measurements.

Intellectual Property Portfolio:

• Patent Strategy: Movano Health owns, jointly owns, or has exclusive rights to 32 issued and in-force patents, covering one or more of its products or product candidates, with expiration dates between November 12, 2039, and December 18, 2040. Additionally, the Company has 5 pending U.S. patent applications, one pending foreign patent application, and one pending Patent Cooperation Treaty ("PCT") International patent application.
• Licensing Programs: Not explicitly detailed as a revenue-generating or strategic program.
• Trade Secret Protection: Relies on unpatented proprietary technology, processes, trade secrets, and know-how, protected through confidentiality agreements with employees, consultants, advisors, and third parties.

Technology Partnerships: Movano Health has formed a strategic partnership with a leading specialty foundry for the manufacturing and supply of its integrated circuits, aiming to strengthen its supply chain and prepare for future volume and competitive pricing.

Leadership & Governance

Executive Leadership Team

Board Composition: The Board of Directors includes Emily Wang Fairbairn (Chair of the Board), Rubén Caballero, Brian Cullinan, Michael Leabman, and Shaheen Wirk. Mr. Caballero, Mr. Cullinan, Ms. Fairbairn, and Mr. Wirk are designated as independent directors. Mr. Cullinan serves as the Chairperson of the Audit Committee and is qualified as an "audit committee financial expert." Dr. Shaheen Wirk joined the board in 2024, bringing over 20 years of healthcare investment experience.

Human Capital Strategy

Workforce Composition:

• Total Employees: 32 (as of December 31, 2024), all employed on a full-time basis.
• Skill Mix: Focus on attracting and retaining highly qualified managerial and engineering personnel.

Talent Management: Acquisition & Retention: Movano Health utilizes equity incentive plans to attract, retain, and reward personnel, aiming to align employee interests with stockholder value.

Environmental & Social Impact

Environmental Commitments: Compliance with environmental provisions has had no material effect on the business. No material capital expenditures for environmental control facilities were incurred in 2024, and none are planned for 2025.

Social Impact Initiatives: The Evie Ring is designed specifically for women, providing continuous health data and actionable insights to help mitigate chronic disease risks. The Company's broader mission is to empower users to make smarter health decisions, increase self-management of chronic conditions, and potentially reduce the frequency of doctor and hospital visits.

Regulatory Environment & Compliance

Regulatory Framework: Industry-Specific Regulations:

• FDA Regulation: The Evie Ring is a general wellness device, not requiring FDA premarket clearance. The EvieMED Ring is a Class II medical device, having received FDA 510(k) clearance for its pulse oximetry feature, and is sold via prescription. Future products, including continuous glucose monitoring and cuffless blood pressure solutions, are targeted for Class II FDA clearance. The Company is subject to extensive FDA regulations governing device development, testing, manufacturing, labeling, marketing, and post-market surveillance (e.g., Quality System Regulation, Medical Device Reporting).
• FCC Regulations: Movano Health's RF-based technology is subject to FCC regulations, including equipment authorization and human exposure to RF energy, expected to be regulated under Part 18 for industrial, scientific, and medical (ISM) equipment.
• Healthcare Privacy Laws: The Company is subject to federal laws like the Health Insurance Portability and Accountability Act of 1996 ("HIPAA") and various state privacy laws (e.g., California Consumer Privacy Act), as well as international regulations like the European Union’s General Data Protection Regulation ("GDPR") for activities outside the U.S., governing the use and disclosure of individually identifiable health information.
• Healthcare Fraud and Abuse Laws: Applicable federal and state laws include the Anti-Kickback Statute, False Claims Act, and the Physician Payment Sunshine Act, which regulate interactions with healthcare providers and payment practices.

Legal Proceedings: Movano Health is not currently a party to any pending legal proceedings that are expected to have a material adverse effect on its business or financial condition.

Tax Strategy & Considerations

Tax Profile:

• Effective Tax Rate: 0% for both 2024 and 2023, primarily due to a full valuation allowance maintained against net deferred tax assets.
• Net Operating Loss Carryforwards: Federal net operating loss carryforwards of approximately $17.1 million as of December 31, 2024, which do not expire.
• Research & Development Credit Carryforwards: Federal R&D credit carryforwards of approximately $2.7 million (expiring starting 2039) and California R&D credit carryforwards of approximately $2.0 million (do not expire) as of December 31, 2024.
• Capitalized Research & Experimental Expenses: In accordance with the 2017 Tax Act, research and experimental expenses are capitalized and amortized over 5 years for domestic expenses and 15 years for foreign expenses, starting in 2022.

Insurance & Risk Transfer

Risk Management Framework: Movano Health employs a risk-based approach to identify and assess cybersecurity threats, including those associated with third-party service providers. The Company implements security controls, conducts third-party cybersecurity testing (including penetration testing), maintains firewall and virus protection software, and holds a cybersecurity insurance policy.